Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (37.5), the stock would be worth ¥-0.6 (109% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -431.9 | ¥6.95 |
0%
|
| 3-Year Average | 37.5 | ¥-0.6 |
-109%
|
| 5-Year Average | 39.5 | ¥-0.64 |
-109%
|
| Industry Average | 41.6 | ¥-0.67 |
-110%
|
| Country Average | 28.8 | ¥-0.46 |
-107%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
B
|
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
|
7.1B CNY | -431.9 | 85.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 14 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 11.9 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 20.7 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 40.2 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 10.6 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Beijing SL Pharmaceutical Co Ltd
Glance View
Beijing SL Pharmaceutical Co Ltd. is a notable player in the pharmaceutical sector, navigating the rigorous demands of healthcare with a focus on innovation and market responsiveness. Born from a deep understanding of the medical field, the company has carved a niche by focusing on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical products. Among its specialties, Beijing SL Pharmaceutical is renowned for its expertise in producing complex chemicals and biologics, which are vital in treating various medical conditions ranging from cardiovascular diseases to neurological disorders. The company puts significant emphasis on research and development, ensuring that its product pipeline remains robust and poised for future growth. The commercial success of Beijing SL Pharmaceutical is largely driven by its keen adaptation to the dynamic healthcare needs both domestically and internationally. The company leverages its extensive distribution network and strategic partnerships with healthcare providers and institutions to ensure that its products reach patients efficiently. By maintaining a diverse product portfolio that caters to pressing medical needs, the company combines patient-centric strategies with astute business acumen to maintain steady revenue streams. Furthermore, its commitment to quality and safety standards reinforces trust among stakeholders, thereby enabling Beijing SL Pharmaceutical to thrive in a competitive landscape. As it continues to expand, the company remains vigilant in enhancing its technological capabilities and market reach, always with an eye on delivering value through health and wellness.
